Curevac AG, once a forerunner in COVID-19 vaccine development but later surpassed, said it would terminate its first effort in the field, CVnCoV, withdrawing it from a rolling review at the EMA to focus instead on development of second-generation mRNA vaccine candidates with Glaxosmithkline plc.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Athenex, Brii, Enzyvant, Genentech, Kintor, Merck, Protagonist, Regeneron, Ridgeback, Roche.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: 4D, Aligos, Astrazeneca, Bicycle, Diurnal, Idorsia, Galmed, Oxurion, Regenxbio, Reistone, Repertoire, Sarepta.
Cambridge, U.K.-based Astrazeneca plc has new data from its long-acting COVID-19 antibody combination, AZD-7442, which aims to provide longer protection, potentially for up to a year. Latest data show the intramuscularly injected drug achieved a statistically significant reduction in severe COVID-19 or death compared to placebo in non-hospitalized patients with mild to moderate symptomatic disease.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Cytosorbents, Limflow, Medalliance, Todos Medical.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Denali, Minervax, Ortho Regenerative, Recursion, Y-Mabs.
PERTH, Australia – Molecular diagnostic company Speedx Pty Ltd. has invested in a Perth-based startup that makes the raw materials needed for polymerase chain reaction (PCR) COVID-19 tests. The two companies will work to develop a new at-home rapid PCR test to ensure Australia can become self-sufficient with producing PCR tests. A rapid PCR test that gives an accurate result in minutes could be used at home or work.
RSS
